Cerus (CERS)
(Delayed Data from NSDQ)
$2.04 USD
-0.01 (-0.49%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $2.03 -0.01 (-0.49%) 7:08 PM ET
3-Hold of 5 3
C Value A Growth D Momentum B VGM
Brokerage Reports
Cerus Corporation [CERS]
Reports for Purchase
Showing records 41 - 60 ( 69 total )
Company: Cerus Corporation
Industry: Medical - Products
Encouraged by 1st US Commercial Hires - Brings Insight into ARC, Largest Potential Customer
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Cerus Corporation
Industry: Medical - Products
In-line 3Q13 Top Line - Key Platelet Submission & Commercial Plans on Track - Red Blood Cell Trial Results Delayed - Maintaining OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Cerus Corporation
Industry: Medical - Products
The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct. 28
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Cerus Corporation
Industry: Medical - Products
UK Validation is Very Encouraging - Represents 1st Step Towards Widespread Use in Large Untapped Geography - Dec. SaBTO Meeting is Key - Reaffirm OP
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Cerus Corporation
Industry: Medical - Products
Optimistic into 3Q13 Call - EU Tone Sounding Better than Usual-Expecting Continued FDA Progress - Maintain OP
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Cerus Corporation
Industry: Medical - Products
Upping Price Target from $6 to $7.50 on Greater Scarcity Value Post Recent Viral Outbreaks and Higher Valuation Umbrella
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Cerus Corporation
Industry: Medical - Products
Company: Cerus Corporation
Industry: Medical - Products
2Q13 Recap - Results Ok -Revs In line and 2013 Guidance Reiterated
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Cerus Corporation
Industry: Medical - Products
The Week Ahead in Life Sciences - Upcoming Events for the Week of July 29
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Cerus Corporation
Industry: Medical - Products
2Q13 Preview - Expecting Ok Results and Good Progress Toward FDA Submission - Minimal 2013 Guidance Risk - Reaffirm OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Cerus Corporation
Industry: Medical - Products
1Q13 Recap - Results Fine - Rev Guidance Reiterated - Higher Burn Understandable in Front of FDA Submissions - Reaffirm OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Cerus Corporation
Industry: Medical - Products
Upping Price Target to $6 from $5 Following Further FDA Clarity on Platelets
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Cerus Corporation
Industry: Medical - Products
4Q12 Recap - Extremely Positive Surprise as FDA Agrees to Look At Platelets
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Cerus Corporation
Industry: Medical - Products
4Q12 Preview - Expecting Solid Base Business - FDA Plasma Submission and Platelet Discussions in Focus - Maintain OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Cerus Corporation
Industry: Medical - Products
3Q12 Results Positive - Surprising Sea Change with FDA Is Very Positive
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Cerus Corporation
Industry: Medical - Products
Company: Cerus Corporation
Industry: Medical - Products
2Q12 Recap - Solid Sales Considering French Rebalance & Fx Headwind - GMs Improve - Guidance Reaffirmed - RBC Programs On Track - Maintain OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Cerus Corporation
Industry: Medical - Products
2Q12 Preview - Expecting Solid Results - Macro & Cash Needs Weighing on Stock - Optimistic on Asian
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Cerus Corporation
Industry: Medical - Products
1Q12 Shaping Up Solidly - Strong French Production in Quarter,
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z